Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

被引:78
作者
Varga, Zsuzsanna [1 ]
Noske, Aurelia [1 ]
Ramach, Constanze [1 ,2 ]
Padberg, Barbara [1 ,3 ]
Moch, Holger [1 ]
机构
[1] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland
[2] Cty Hosp St Gallen, Inst Pathol, St Gallen, Switzerland
[3] Cty Hosp Aarau, Inst Pathol, Aarau, Switzerland
关键词
HER2; Fluorescence in situ hybridization (FISH); Immunohistochemistry; Breast cancer; CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY; HIGH CONCORDANCE; AMPLIFICATION; FISH; RECOMMENDATIONS; IMPLEMENTATION; IHC; ER;
D O I
10.1186/1471-2407-13-615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The gold standard of HER2 status assessment in breast cancer is still debated. Immunohistochemistry (IHC) and in-situ technology as fluorescent-labeled methodology (FISH) can be influenced by pre-analytical factors, assay-conditions and interpretation of test results. We retrospectively conducted this quality control study and analyzed HER2 test results in breast cancer within the routine diagnostic service in a single institution over a period of 12 years. We addressed the question how stable and concordant IHC and FISH methods are and whether HER2 positivity rate has changed over this period. Methods: Data of 7714 consecutive HER2-FISH-assays in a period of 12 years (2001-2012) on breast cancer biopsies and excision specimens were retrospectively analyzed. From 2001 to 2004, FISH tests were performed from all cases with IHC score 3+ and 2+ (and in some tumors with IHC score 1+ and 0). From 2005-2010, HER2 status was only determined by FISH. From 2011-2012, all breast carcinomas were analyzed by both IHC and FISH. Scoring and cut-off-definition were done according to time-current ASCO-CAP and FDA-guidelines. Results: Between 2001-2004, IHC score 3+ was diagnosed in 22% of cases, 69% of these 3+ cases were amplified by FISH. 6% of IHC score 0/1+ cases were amplified by FISH. There was a mean amplification rate of 15.8% (range 13-19%) using FISH only HER2-assays (2005-2010). Starting 2008, a slight drop in the amplification rate from 17% to 14% was noticed due to the modified ASCO-criteria in 2007. From 2011-2012, 12% of cases were 3+ by IHC, 84% of them were amplified by FISH. Less than 1% of IHC score 0/1+ cases were amplified by FISH. Concordance between FISH and IHC increased from 83% to 97%. Conclusions: Our quality control study demonstrates that HER2 positivity rate remained stable by FISH-technology but showed a significant variation by IHC over the analyzed 12 years. Improvement in concordance rate was due to standardization of pre-analytical factors, scoring and interpretation.
引用
收藏
页数:9
相关论文
共 39 条
  • [1] [Anonymous], 2007, J CLIN ONCOL, DOI DOI 10.1200/JCO.2006.09.2775
  • [2] Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
    Arnouldi, Laurent
    Roger, Pascal
    MacGrogan, Gaetan
    Chenard, Marie-Pierre
    Balaton, Andre
    Beauclair, Sophie
    Penault-Llorca, Frederique
    [J]. MODERN PATHOLOGY, 2012, 25 (05) : 675 - 682
  • [3] Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation
    Atkinson, Roscoe
    Mollerup, Jens
    Laenkholm, Anne-Vibeke
    Verardo, Mark
    Hawes, Debra
    Commins, Deborah
    Engvad, Birte
    Correa, Adrian
    Ehlers, Charlotte Cort
    Nielsen, Kirsten Vang
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2011, 135 (08) : 1010 - 1016
  • [4] The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays
    Babic, Andrea
    Loftin, Isabell R.
    Stanislaw, Stacey
    Wang, Maria
    Miller, Rachel
    Warren, Stephanie M.
    Mang, Wenjun
    Lau, Alexandria
    Miller, Melanie
    Wu, Ping
    Padilla, Mary
    Grogan, Thomas M.
    Pestic-Dragovich, Lidija
    McElhinny, Abigail S.
    [J]. METHODS, 2010, 52 (04) : 287 - 300
  • [5] The clinical evaluation of HER-2 status: which test to use?
    Bartlett, J
    Mallon, E
    Cooke, T
    [J]. JOURNAL OF PATHOLOGY, 2003, 199 (04) : 411 - 417
  • [6] Evaluating HER2 amplification and overexpression in breast cancer
    Bartlett, JMS
    Going, JJ
    Mallon, EA
    Watters, AD
    Reeves, JR
    Stanton, P
    Richmond, J
    Donald, B
    Ferrier, R
    Cooke, TG
    [J]. JOURNAL OF PATHOLOGY, 2001, 195 (04) : 422 - 428
  • [7] External Quality Assurance of HER2 FISH and ISH Testing Three Years of the UK National External Quality Assurance Scheme
    Bartlett, John M. S.
    Ibrahim, Merdol
    Jasani, Bharat
    Morgan, John M.
    Ellis, Ian
    Kay, Elaine
    Connolly, Yvonne
    Campbell, Fiona
    O'Grady, Anthony
    Barnett, Sarah
    Miller, Keith
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (01) : 106 - 111
  • [8] Current perspectives on HER2 testing:: A review of national testing guidelines
    Bilous, M
    Dowsett, M
    Hanna, W
    Isola, J
    Lebeau, A
    Moreno, A
    Penault-Llorca, F
    Rüschoff, J
    Tomasic, G
    de Vijver, MV
    [J]. MODERN PATHOLOGY, 2003, 16 (02) : 173 - 182
  • [9] Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study
    Bilous, M
    Ades, C
    Armes, J
    Bishop, J
    Brown, R
    Cooke, B
    Cummings, M
    Farshid, G
    Field, A
    Morey, A
    McKenzie, P
    Raymond, W
    Robbins, P
    Tan, L
    [J]. BREAST, 2003, 12 (02) : 92 - 98
  • [10] Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
    Bilous, Michael
    Morey, Adrienne L.
    Armes, Jane E.
    Bell, Richard
    Button, Peter H.
    Cummings, Margaret C.
    Fox, Stephen B.
    Francis, Glenn D.
    Waite, Brigid
    McCue, Glenda
    Raymond, Wendy A.
    Robbins, Peter D.
    Farshid, Gelareh
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (02) : 617 - 624